Funding, regulation, and the business of longevity — who is investing in aging research, how regulatory bodies are responding, and what it means for when new treatments might reach the public. The context behind the science.
Funding, regulation, and the business of longevity — who is investing in aging research, how regulatory bodies are responding, and what it means for when new treatments might reach the public. The context behind the science.